Affiliation:
1. Department of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China
Abstract
Objective. To study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity. Methods. Abdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness. Results. After 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA1c) decreased from
% to
% (
,
). The weight decreased from
kg to
kg (
,
). Waist circumference before treatment was
cm, and after treatment was
cm (
,
). Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those before treatment. TC decreased from
mmol/L to
mmol/L (
,
). TG was 1.89 (1.48-3.17) and then to
(
). LDL-C decreased from
mmol/L to
mmol/L (
,
). HDL-C increased by 1.7% after treatment, with no significant difference (
). More importantly, the thickness of EAT decreased from 5.0 (5.0-7.0) mm to
mm (
) after liraglutide administered for 3 months. Conclusion. Liraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献